Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Clinical Research and Equipment Industry Analysis

UpdatedNov 14, 2025
DataAggregated Company Financials
Companies63
  • 7D2.0%
  • 3M12.1%
  • 1Y3.6%
  • YTDn/a

In the last week, the Clinical Research and Equipment industry is up 2.0%, with Danaher up 4.8%. Meanwhile, West Pharmaceutical Services actually underperformed within the industry, shrinking 5.1% in the last week. This takes the industry's 12 month performance to a gain of 3.6%. As for the next few years, earnings are expected to grow by 19% per annum.

Industry Valuation and Performance

Has the U.S. Clinical Research and Equipment Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 18 Nov 2025US$657.5bUS$145.7bUS$12.2b34.8x54.1x4.5x
Thu, 16 Oct 2025US$615.0bUS$144.3bUS$14.6b32.5x42.3x4.3x
Sat, 13 Sep 2025US$580.3bUS$144.3bUS$14.6b28.6x39.9x4x
Mon, 11 Aug 2025US$550.7bUS$144.2bUS$14.4b28.5x38.2x3.8x
Wed, 09 Jul 2025US$537.0bUS$142.9bUS$9.1b36x58.8x3.8x
Fri, 06 Jun 2025US$514.9bUS$142.9bUS$9.2b34.8x56.2x3.6x
Sun, 04 May 2025US$523.7bUS$142.4bUS$9.7b37.8x54.3x3.7x
Tue, 01 Apr 2025US$575.3bUS$142.5bUS$10.0b37.6x57.8x4x
Thu, 27 Feb 2025US$619.3bUS$143.3bUS$9.8b38.4x63.4x4.3x
Sat, 25 Jan 2025US$702.6bUS$142.4bUS$10.2b45.1x68.8x4.9x
Mon, 23 Dec 2024US$652.4bUS$142.4bUS$10.2b44.3x63.8x4.6x
Wed, 20 Nov 2024US$630.4bUS$142.4bUS$10.4b41.6x60.8x4.4x
Fri, 18 Oct 2024US$725.2bUS$141.8bUS$8.5b37.1x85.4x5.1x
Sun, 15 Sep 2024US$740.7bUS$141.8bUS$8.5b37.5x87.2x5.2x
Tue, 13 Aug 2024US$727.5bUS$141.5bUS$8.5b38.5x85.8x5.1x
Thu, 11 Jul 2024US$662.3bUS$141.3bUS$12.2b39.8x54.4x4.7x
Sat, 08 Jun 2024US$718.4bUS$141.3bUS$12.2b37.7x59x5.1x
Mon, 06 May 2024US$711.4bUS$141.7bUS$12.5b38.9x56.9x5x
Wed, 03 Apr 2024US$737.7bUS$142.0bUS$12.8b43.4x57.7x5.2x
Fri, 01 Mar 2024US$739.0bUS$142.2bUS$12.7b43.8x58x5.2x
Sun, 28 Jan 2024US$698.4bUS$153.8bUS$14.2b35.5x49.3x4.5x
Tue, 26 Dec 2023US$698.8bUS$153.8bUS$14.2b37.5x49.1x4.5x
Thu, 23 Nov 2023US$616.3bUS$153.8bUS$14.0b33.5x44x4x
Sat, 21 Oct 2023US$607.7bUS$154.6bUS$11.2b31.3x54.2x3.9x
Mon, 18 Sep 2023US$697.4bUS$154.6bUS$11.2b33.4x62.2x4.5x
Wed, 16 Aug 2023US$719.3bUS$154.7bUS$11.4b32.4x62.9x4.7x
Fri, 14 Jul 2023US$704.1bUS$155.5bUS$12.7b29.1x55.5x4.5x
Sun, 11 Jun 2023US$680.2bUS$152.4bUS$12.5b29.1x54.4x4.5x
Tue, 09 May 2023US$697.5bUS$152.4bUS$12.9b30.5x54.2x4.6x
Thu, 06 Apr 2023US$722.3bUS$154.6bUS$10.8b26.7x66.9x4.7x
Sat, 04 Mar 2023US$739.7bUS$154.5bUS$10.9b31x68x4.8x
Mon, 30 Jan 2023US$761.7bUS$155.5bUS$9.0b31.1x84.7x4.9x
Wed, 28 Dec 2022US$744.3bUS$155.2bUS$8.8b28.6x84.8x4.8x
Fri, 25 Nov 2022US$762.8bUS$155.1bUS$8.8b28.3x87x4.9x
Price to Earnings Ratio

87x


Total Market Cap: US$762.8bTotal Earnings: US$8.8bTotal Revenue: US$155.1bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Clinical Research and Equipment Industry Price to Earnings3Y Average 61.4x202320242025
Current Industry PE
  • Investors are pessimistic on the American Life Sciences Tools and Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 54.1x which is lower than its 3-year average PE of 61.4x.
  • The industry is trading close to its 3-year average PS ratio of 4.5x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences Tools and Services industry have grown 12% per year over the last three years.
  • Meanwhile revenues for these companies have declined 2.1% per year.
  • This means that less sales are being generated overall, but since cost of doing business is lower, profits have been increasing.

Industry Comparison

How does U.S. Clinical Research and Equipment compare with similar industries?

US Market-0.39%
Healthcare3.77%
Life Sciences1.98%
Clinical Research and Equipment1.98%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
DHR DanaherUS$220.444.4%
+US$6.5b		-4.2%PE44.4x
IQV IQVIA HoldingsUS$216.121.4%
+US$522.8m		13.1%PE28.7x
QGEN QiagenUS$44.132.2%
+US$208.2m		4.7%PE23.6x
RGEN RepligenUS$149.002.3%
+US$188.0m		20.7%PE4825.8x
TECH Bio-TechneUS$58.612.0%
+US$179.2m		-12.3%PE117.2x

Latest News

TEM
US$68.48
Tempus AI
7D
-4.6%
1Y
26.7%
TMO
US$578.71
Thermo Fisher Scientific
7D
0.4%
1Y
15.4%
MTD
US$1,403.08
Mettler-Toledo International
7D
-2.1%
1Y
19.5%

MTD: Share Repurchases And Acquisitions Will Drive Measured Gains Ahead

Analysts have raised their price target for Mettler-Toledo International from $1,343.36 to $1,492.64. This change reflects improved expectations for revenue growth and updated financial assumptions.
ILMN
US$120.67
Illumina
7D
-0.9%
1Y
-7.7%

ILMN: Future Momentum Will Depend On China Recovery And Efficiency Gains

Analysts have modestly raised their price target on Illumina, increasing fair value estimates from approximately $113.58 to $117.74. This reflects improved revenue growth and operational efficiency, despite mixed business visibility and regional challenges.
RGEN
US$152.37
Repligen
7D
4.6%
1Y
23.5%
BLFS
US$24.07
BioLife Solutions
7D
-8.4%
1Y
17.6%
QGEN
US$44.32
Qiagen
7D
2.7%
1Y
5.1%

QGEN: Improving Sentiment And Stable Markets Will Set Stage For Future Upside

Analysts have slightly lowered their price target for Qiagen, reducing it by approximately $0.86 to reflect stable end markets. They also acknowledge that improvement is expected as investment sentiment stabilizes.
DHR
US$221.21
Danaher
7D
4.8%
1Y
-3.8%
TXG
US$15.89
10x Genomics
7D
-7.0%
1Y
20.6%

There's Reason For Concern Over 10x Genomics, Inc.'s (NASDAQ:TXG) Massive 42% Price Jump

Nov 14
There's Reason For Concern Over 10x Genomics, Inc.'s (NASDAQ:TXG) Massive 42% Price Jump
MEDP
US$590.09
Medpace Holdings
7D
-1.7%
1Y
91.0%
WAT
US$379.40
Waters
7D
0.8%
1Y
6.7%
STVN
US$22.08
Stevanato Group
7D
-8.9%
1Y
24.3%

STVN: Expansion Of German Manufacturing Facility Will Fuel Future Upside

Narrative Update on Stevanato Group Price Target Analysts have raised their price target for Stevanato Group slightly, increasing it from $28.62 to $28.80. This change is attributed to modest improvements in projected revenue growth and profit margins, despite a higher discount rate.
TECH
US$59.38
Bio-Techne
7D
3.3%
1Y
-11.2%

Bio-Techne Corporation (NASDAQ:TECH) Just Released Its First-Quarter Earnings: Here's What Analysts Think

Nov 08
Bio-Techne Corporation (NASDAQ:TECH) Just Released Its First-Quarter Earnings: Here's What Analysts Think
ICLR
US$162.18
ICON
7D
2.9%
1Y
-13.4%

ICLR: Operational Resilience And Leadership Transition Will Support Momentum Next Year

The analyst price target for ICON has edged lower by approximately $0.67 to $208.27, as analysts cite ongoing concerns about margin pressure and a slightly more cautious revenue growth outlook. Analyst Commentary Analyst sentiment on ICON remains divided, with both encouraging signals and pressing concerns for investors to consider.
WST
US$261.36
West Pharmaceutical Services
7D
-5.1%
1Y
-14.9%

WST: Sustained Earnings Momentum Will Drive Confidence Into 2026

West Pharmaceutical Services has seen its average analyst price target rise from approximately $321 to $351. Analysts cite continued growth drivers and improved market conditions following a strong quarterly performance.
IQV
US$220.61
IQVIA Holdings
7D
3.5%
1Y
15.5%

IQV: Margins and Market Visibility Will Drive Outperformance Versus Peers

The analyst price target for IQVIA Holdings has been raised from $223.42 to $246.84. Analysts point to stabilizing profit margins, modestly higher growth expectations, and increasing industry confidence as key drivers of the upward revision.